Siemens gets FDA nod for ELF test for liver fibrosis

By LabPulse.com staff writers

August 24, 2021 -- Siemens Healthineers has been granted marketing authorization from the U.S Food and Drug Administration (FDA) for its Enhanced Liver Fibrosis (ELF) test, an IVD assay for patients with advanced liver fibrosis.

ELF is a noninvasive blood test intended for use with the company's Advia Centaur XP immunoassay system. The test provides a numeric score that is automatically generated via an algorithm and is used to assess the likelihood of progressing to cirrhosis and liver-related clinical events in patients with severe or advanced fibrosis (F3 or F4) due to nonalcoholic steatohepatitis (NASH).

The ELF test's marketing authorization in the U.S. results from Siemens' clinical and research partnership with Gilead Sciences, according to the company. The authorization follows the breakthrough device designation granted by the FDA to the test in November 2018.

Siemens posts strong revenue, earnings growth in Q1
Benefiting from ongoing demand for products related to the COVID-19 pandemic and recovery in its core businesses, Siemens Healthineers exceeded market...
Siemens' SARS-CoV-2 test measures neutralizing antibodies
Siemens Healthineers has announced that its SARS-CoV-2 immunoglobin G antibody test is able to measure neutralizing antibodies for the virus.
Siemens Healthineers posts dip in Q4 revenues
Siemens Healthineers posted a 2% decline in revenues for the company's fourth quarter of fiscal 2020. Net income also slipped for the period, but the...
Siemens donates $500K to Testing for America
Siemens Healthineers and the Siemens Foundation have partnered with Testing for America to donate $500,000 in funding and COVID-19 testing to historically...
Siemens offers liver fibrosis blood test in U.S.
Siemens Healthineers said it is now providing its Enhanced Liver Fibrosis (ELF) testing service in 49 U.S. states, Washington, DC, and Puerto Rico.

Copyright © 2021 LabPulse.com

Last Updated np 9/1/2021 12:07:59 PM